Ranexa may reduce chest pain in patients with type 2 diabetes

According to a study presented at the American College of Cardiology (ACC) meetings in San Francisco and to be published in the Journal of the American College of Cardiology, the drug Ranexa (ranolazine) may be able to reduce chest pain in individuals with type 2 diabetes, especially those with poor blood glucose control. It may even have a secondary benefit: lowering blood sugar levels.

Says lead study author Dr. Mikhail Kosiborod, "Ranolazine is an effect anti-anginal drug in patients with diabetes and may also have a glucose-lowering effect. If the glucose-lowing action of ranolazine is confirmed in future studies, patients with diabetes and angina may derive a dual benefit from this drug."

Gilead Sciences, Inc., the company that makes Ranexa, funded the study.

Read the full story

Sign up for our newsletter
  • Get diabetes supplies
    delivered to your door.
  • Find companies that offer free
    delivery of the brands you want.

  • Diabetes supplies
     CPAP mask and tubing
  • How would you describe yourself?

  • Do you have Medicare as your primary insurance?
  • Yes No

Related Medications Content

Add a comment
Google Plus
(required) *
(required,will not be displayed) *
Can't read this?
Get two new words
Listen to the words